{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:44:17Z","timestamp":1778640257612,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.4065\/mcp.2010.0674","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T03:22:32Z","timestamp":1299036152000},"page":"250-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"title":["Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum \u03b2-Lactamase\u2013Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa"],"prefix":"10.4065","volume":"86","author":[{"given":"Souha S.","family":"Kanj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeina A.","family":"Kanafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/mcp.2010.0674_bib1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/605539","article-title":"Bad bugs, no drugs: no ESCAPE revisited","volume":"49","author":"Peterson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of \u03b2-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.4065\/mcp.2010.0674_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0674_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1469-0691.2007.01863.x","article-title":"Extended-spectrum \u03b2-lactamases: structure and kinetic mechanism","volume":"14","author":"Page","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.4065\/mcp.2010.0674_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.4065\/mcp.2010.0674_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.4065\/mcp.2010.0674_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile \u03b2-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.4065\/mcp.2010.0674_bib8","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.49.7.3018-3020.2005","article-title":"Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection","volume":"49","author":"Bratu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3201\/eid1208.060291","article-title":"Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing","volume":"12","author":"Tenover","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.4065\/mcp.2010.0674_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp0804651","article-title":"Antibiotic-resistant bugs in the 21st century: a clinical super-challenge","volume":"360","author":"Arias","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2010.0674_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijmm.2010.04.005","article-title":"Resistance to cephalosporins and carbapenems in gram-negative bacterial pathogens","volume":"300","author":"Pfeifer","year":"2010","journal-title":"Int J Med MicroBiol"},{"key":"10.4065\/mcp.2010.0674_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkl199","article-title":"In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"58","author":"Rossi","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkm310","article-title":"Antimicrobial susceptibility among organisms from the Asia\/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline","volume":"60","author":"Reinert","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.48.1.1-14.2004","article-title":"Growing group of extended-spectrum \u03b2-lactamases: the CTX-M enzymes","volume":"48","author":"Bonnet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1086\/604713","article-title":"A multinational survey of risk factors for infection with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in nonhospitalized patients","volume":"49","author":"Ben-Ami","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing \u03b2-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archinte.165.12.1430","article-title":"Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium","volume":"165","author":"Bratu","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.4065\/mcp.2010.0674_bib20","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1128\/AAC.49.10.4423-4424.2005","article-title":"Plasmid-mediated carbapenem-hydrolyzing \u03b2-lactamase KPC in a Klebsiella pneumoniae isolate from France","volume":"49","author":"Naas","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/AAC.01053-06","article-title":"Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China","volume":"51","author":"Wei","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib22","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1128\/AAC.00186-06","article-title":"First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America","volume":"50","author":"Villegas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum \u03b2-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.47102\/annals-acadmedsg.V37N10p831","article-title":"Ertapenem for treatment of extended-spectrum \u03b2-lactamase-producing and multidrug-resistant gram-negative bacteraemia","volume":"37","author":"Lye","year":"2008","journal-title":"Ann Acad Med Singapore"},{"key":"10.4065\/mcp.2010.0674_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/600036","article-title":"Doripenem","volume":"49","author":"Paterson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/dkn311","article-title":"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies","volume":"62","author":"Kelesidis","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.4065\/mcp.2010.0674_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.38.4.767","article-title":"Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important \u03b2-lactamases","volume":"38","author":"Payne","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib33","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"168","author":"Rodriguez-Bano","year":"2008","journal-title":"Arch Intern Med"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0674_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1469-0691.2007.01864.x","article-title":"Antibiotic policy and prescribing strategies for therapy of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam","volume":"14","author":"Peterson","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.4065\/mcp.2010.0674_bib35","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib36","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodriguez-Bano","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib38","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.hrtlng.2004.11.001","article-title":"Extended spectrum \u03b2-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B","volume":"34","author":"Parchuri","year":"2005","journal-title":"Heart Lung"},{"key":"10.4065\/mcp.2010.0674_bib40","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1086\/514754","article-title":"Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review","volume":"28","author":"Segal-Maurer","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijantimicag.2008.01.011","article-title":"Colistin susceptibility testing by Etest and disk diffusion methods","volume":"31","author":"Galani","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.4065\/mcp.2010.0674_bib42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jac\/34.6.853","article-title":"Fosfomycin trometamol","volume":"34","author":"Reeves","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-007-0456-4","article-title":"Antimicrobial susceptibility of multidrug-resistant gram negative bacteria to fosfomycin","volume":"27","author":"Falagas","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10096-007-0370-9","article-title":"In vitro activity of temocillin against prevalent extended-spectrum \u03b2-lactamases producing Enterobacteriaceae from Belgian intensive care units","volume":"26","author":"Glupczynski","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/00365540701367801","article-title":"Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam","volume":"39","author":"Nicolle","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000319952","article-title":"A multicenter, randomized controlled clinical study on biapenem and imipenem\/cilastatin injection in the treatment of respiratory and urinary tract infections","volume":"56","author":"Jia","year":"2010","journal-title":"Chemotherapy"},{"key":"10.4065\/mcp.2010.0674_bib49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkm063","article-title":"Activity of faropenem against cephalosporin-resistant Enterobacteriaceae","volume":"59","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib50","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.49.8.3239-3250.2005","article-title":"In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem","volume":"49","author":"Koga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0674_bib51","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1469-0691.2007.01852.x","article-title":"Other antimicrobials of interest in the era of extended-spectrum \u03b2-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.4065\/mcp.2010.0674_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dki175","article-title":"Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents","volume":"56","author":"Bratu","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.01114-07","article-title":"Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-\u03b2-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program","volume":"52","author":"Castanheira","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib54","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkq108","article-title":"Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection","volume":"65","author":"Hirsch","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/526775","article-title":"Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline","volume":"46","author":"Anthony","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijantimicag.2007.07.024","article-title":"Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel","volume":"30","author":"Samra","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.4065\/mcp.2010.0674_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jhin.2010.03.021","article-title":"Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 \u03b2-lactamase resistant to colistin","volume":"76","author":"Kontopoulou","year":"2010","journal-title":"J Hosp Infect"},{"key":"10.4065\/mcp.2010.0674_bib58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.01235-09","article-title":"In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and\/or colistin","volume":"54","author":"Endimiani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib59","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1128\/AAC.01768-09","article-title":"In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli","volume":"54","author":"Urban","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib60","unstructured":"Melchers R, Mavridou E, Van Mil A, Motyl MR, Mouton JW. In vitro activity of imipenem alone and in combination with MK-7655: a new \u03b2-lactamase inhibitor [poster F1-2138]. Poster presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010."},{"key":"10.4065\/mcp.2010.0674_bib61","unstructured":"Livermore DM. Spectrum and potential of NXL104 as a \u03b2-lactamase inhibitor [poster 1849]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010."},{"key":"10.4065\/mcp.2010.0674_bib62","unstructured":"Sheri A, Pagadala SR, Young K, et al. Optimization of a carbapenem\/\u03b2-lactamase inhibitor combination against highly resistant gram-negative microorganisms [poster F1-1496]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010."},{"key":"10.4065\/mcp.2010.0674_bib63","unstructured":"Jacobs MR, Bajaksouzian S, Butler MM, et al. Activity of novel bis-in-dole agents against carbapenemase-producing Klebsiella pneumoniae [poster F1-1632]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010."},{"key":"10.4065\/mcp.2010.0674_bib64","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1128\/AAC.00207-10","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib65","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.46.6.2032-2034.2002","article-title":"Efficacy of \u03b2-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-\u03b2-lactamase-producing strain of Pseudomonas aeruginosa","volume":"46","author":"Bellais","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib66","first-page":"144","article-title":"Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study [in Spanish]","volume":"23","author":"Gimeno","year":"2010","journal-title":"Rev Esp Quimioter"},{"key":"10.4065\/mcp.2010.0674_bib67","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1128\/AAC.00381-08","article-title":"In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States","volume":"52","author":"Pillar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib68","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.48.8.3086-3092.2004","article-title":"Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transcon jugants and resistance selection potential","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib69","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.00060-06","article-title":"Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa","volume":"50","author":"Kaye","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib70","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00134-007-0675-2","article-title":"Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"33","author":"Kallel","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.4065\/mcp.2010.0674_bib71","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib72","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"key":"10.4065\/mcp.2010.0674_bib73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1179\/joc.2010.22.3.175","article-title":"Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use","volume":"22","author":"Daikos","year":"2010","journal-title":"J Chemother"},{"key":"10.4065\/mcp.2010.0674_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.4065\/mcp.2010.0674_bib75","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1128\/AAC.36.3.620","article-title":"Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol","volume":"36","author":"Korvick","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib76","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"key":"10.4065\/mcp.2010.0674_bib77","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.47.9.2756-2764.2003","article-title":"Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia","volume":"47","author":"Chamot","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib78","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus \u03b2 lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials [published correction appears in BMJ. 2004;328(7444):884]","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"10.4065\/mcp.2010.0674_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(04)01108-9","article-title":"Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? a meta-analysis","volume":"4","author":"Safdar","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/dki204","article-title":"In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with \u03b2-lactams and amikacin","volume":"56","author":"Drago","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 2","key":"10.4065\/mcp.2010.0674_bib81","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1086\/426190","article-title":"Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa","volume":"40","author":"Lister","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib82","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib83","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1128\/JCM.39.6.2072-2078.2001","article-title":"Nosocomial outbreak due to a multi-resistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of \u03b2-lactam resistance","volume":"39","author":"Dubois","year":"2001","journal-title":"J Clin MicroBiol"},{"key":"10.4065\/mcp.2010.0674_bib84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3349\/ymj.2010.51.1.111","article-title":"In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains","volume":"51","author":"Dundar","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.4065\/mcp.2010.0674_bib85","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkf211","article-title":"Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs","volume":"50","author":"Fish","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib86","first-page":"896","article-title":"Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa","volume":"101","author":"Zuravleff","year":"1983","journal-title":"J Lab Clin Med"},{"key":"10.4065\/mcp.2010.0674_bib87","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000221850","article-title":"Evaluation of different antibiotic actions combined with rifampicin: in vitro synergism against Pseudomonas and Proteus","volume":"21","author":"Urena","year":"1975","journal-title":"Chemotherapy"},{"key":"10.4065\/mcp.2010.0674_bib88","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.47.3.905-909.2003","article-title":"Synergistic activity of colistin and ceftazidime against multi-antibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"47","author":"Gunderson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib89","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.46.4.1105-1107.2002","article-title":"Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis","volume":"46","author":"Saiman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2005.10.012","article-title":"In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units","volume":"27","author":"Timurkaynak","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.4065\/mcp.2010.0674_bib91","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/jac\/dkp384","article-title":"Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index","volume":"65","author":"Milne","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib92","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.34.2.269","article-title":"Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia","volume":"34","author":"Brown","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2010.0674_bib93","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"358","author":"Ratjen","year":"2001","journal-title":"Lancet"},{"key":"10.4065\/mcp.2010.0674_bib94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.4065\/mcp.2010.0674_bib95","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/432583","article-title":"Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"41","author":"Kwa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib96","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0924-8579(00)00344-7","article-title":"An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem\/cilastatin in the intravenous treatment of hospitalised patients with pneumonia","volume":"17","author":"Feldman","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.4065\/mcp.2010.0674_bib97","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1128\/IAI.00815-08","article-title":"An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity","volume":"77","author":"Baer","year":"2009","journal-title":"Infect Immun"},{"key":"10.4065\/mcp.2010.0674_bib98","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.4065\/mcp.2010.0674_bib99","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2010.0674_bib100","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1016\/j.bmc.2004.08.039","article-title":"Novel imidazole substituted 6-methylidene-penems as broad spectrum \u03b2-lactamase inhibitors","volume":"12","author":"Venkatesan","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.4065\/mcp.2010.0674_bib101","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.coph.2009.08.006","article-title":"Prospects for the next anti-Pseudomonas drug","volume":"9","author":"Page","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.4065\/mcp.2010.0674_bib102","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2010.0674_bib103","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1345\/aph.1M717","article-title":"High-dose continuous infusion \u03b2-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients","volume":"44","author":"Moriyama","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2010.0674_bib104","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/mcp.2010.0674_bib105","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"10.4065\/mcp.2010.0674_bib106","unstructured":"Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [poster L-1564b]. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 27-30, 2006."},{"key":"10.4065\/mcp.2010.0674_bib107","unstructured":"Bulik CC, Nicolau DP. In vivo efficacy of 1 g human simulated prolonged infusion doripenem (DOR) against carbapenemase producing Klebsiella pneumoniae (KPC) [poster A1-014]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010."}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611601602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611601602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:07:57Z","timestamp":1710457677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611601602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0025619611601602"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0674","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum \u03b2-Lactamase\u2013Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}